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A global outbreak of severe acute respiratory syn-
drome (SARS) caused by a novel coronavirus began in
March 2003. The rapid emergence of SARS and the sub-
stantial illness and death it caused have made it a critical
public health issue. Because no effective treatments are
available, an intensive effort is under way to identify and
test promising antiviral drugs. Here, we report that recom-
binant human interferon -β 1a potently inhibits SARS coro-
navirus replication in vitro.
T
he recent global outbreak of severe acute respiratory
syndrome (SARS) has quickly gained notoriety as a
newly emerging infectious disease. The etiologic agent
was identified as a coronavirus (SARS-CoV) that is not
closely related to any of the previously characterized coro-
naviruses (1,2). As of September 26, 2003, a total of 8,098
probable cases of SARS have occurred with 774 deaths.
No antiviral treatments are currently available against
SARS-CoV. SARS cases have been treated symptomati-
cally according to the severity of the illness. A treatment
protocol consisting of antibacterial agents and a combina-
tion of ribavirin and methylprednisolone was recently pro-
posed. However, the therapeutic value of ribavirin remains
uncertain because it has no activity against SARS-CoV in
vitro. Molecular modeling studies suggest that rhinovirus
3Cpro inhibitors may be useful for SARS therapy, but
results of recent in vitro testing of the lead molecule,
AG7088, were negative (3).
Previous studies showed that some coronaviruses,
including avian infectious bronchitis virus, murine hepati-
tis virus, and human coronavirus 229E, are susceptible to
type I interferons in vitro or in vivo (4–7). Therefore, we
evaluated the in vitro efficacy of a recombinant human
type I interferon (IFN), IFN-β 1a (Serono International,
Geneva, Switzerland) against three different isolates of
SARS-CoV (Tor2 and Tor7 and Urbani) using yield reduc-
tion assays. The IFN-β 1a preparation employed in this
study was selected because it is currently used as part of
the most effective treatment regimen for relapsing forms of
multiple sclerosis (8), and more importantly, because it
was shown to have antiviral activity (as measured in a
vesicular stomatitis virus cytopathic assay system) 14
times greater than the currently available treatment using
IFN-β 1b (9).
In the current study, Vero E6 cells were treated with
concentrations (5,000 to 500,000 IU/mL) of IFN-β 1a
either 24 h before or 1 h after inoculation with the SARS-
CoV (multiplicity of infection 0.1 PFU/cell), and moni-
tored for cytopathic effect and production of infectious
SARS-CoV at 24, 48, and 72 h postinfection. Inhibition of
the SARS-CoVs by IFN-β 1a was dependent on both time
of drug administration and time of culture sampling after
SARS-CoV infection. Production of infectious SARS-
CoV was potently inhibited (>99.5% or 2.00 log10
PFU/mL) at 24 h postinfection by pretreatment of Vero E6
cells with IFN-β 1a at all concentrations tested (Figure 1).
By 72 h postinfection, inhibition of SARS-CoVproduction
by IFN-β 1a had declined for all three SARS-CoVs, with
inhibition (>70%) being detected in the Tor7 (Figure 1)
and Urbani isolates (data not shown). IFN-β 1a was some-
what less effective at inhibiting SARS-CoV replication
when employed after infection of cultures (Figure 1).
Nonetheless, production of infectious SARS-CoVs was
considerably reduced (>90% or 1.00 log10 PFU/mL) at 24
and 48 h postinfection. Protection of Vero E6 monolayers
against SARS-CoV–induced cytopathic effects by prein-
fection or postinfection treatment with IFN-β 1a was dra-
matic, even at 72 h postinfection (Figure 2). Additional
concentrations of IFN-β 1a (0.5–5,000 IU/mL) were tested
to determine the 50% inhibitory concentration (IC50).
Pretreatment of Vero E-6 cells with concentrations as low
as 50 IU/mL, or posttreatment of cells with concentrations
at 500 IU/mL, provided a 50% reduction with the Tor2 iso-
late at 24 h postinfection.
Faced with a burgeoning epidemic of SARS cases and
a lack of effective treatment options, identifying com-
pounds with antiviral activity that could be potential ther-
apeutics has become a high priority. Our report suggests
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Medical Center, Cincinnati, Ohio, USAthat IFN-β 1a may be effective as a treatment for SARS-
CoV infections. As noted above, IFN-β 1a is currently
being used for a variety of clinical indications, including
multiple sclerosis, and has shown dose-dependent efficacy
in several clinical trials. Importantly, IFN-β 1a exhibited
potent antiviral activity at doses that have already been
shown to have acceptable safety profiles in animals (10).
Thus, we report the identification of a compound that may
be suitable for rapid development as a treatment for SARS-
CoV infection.
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Figure 1. Interferon (IFN)-β 1a inhibi-
tion of SARS-CoV replication in Vero
E6 cells. Top panels, Vero E6 cells
were incubated in the absence (-▲-)
or presence of IFN-β 1a added 24 h
before infection with the Tor2 (left) or
Tor7 (right) isolate of SARS Co-V.
Bottom panels, Vero E6 cells were
incubated in the absence (-▲-) or
presence of IFN-β 1a added 1 h after
infection with the Tor2 (left) or Tor7
(right) isolate of SARS Co-V. Three
concentrations of IFN-β 1a were
employed for both studies: 5,000
IU/mL (-❏-), 50,000 IU/mL (-■-),
500,000 IU/mL (-■-) Samples of over-
lying media were collected at 24, 48,
and 72 h postinfection and analyzed
by plaque assay on Vero E6 cells.
Figure 2. Interferon (IFN)-β 1a inhibition of SARS-CoV cytopathic-
ity in Vero E6 cells. Vero E6 cells were infected with the Tor2 iso-
late of SARS-CoV and incubated for 72 h in the absence (left
panel) or presence (right panel) of 500,000 IU of recombinant
human IFN-β 1a. Cell rounding and detachment were prominent in
the absence of IFN-β 1a. Minimal cell rounding or death was noted
in the intact monolayer at 72 h postinoculation in the presence of
IFN-β 1a (note: IFN-β 1a administered 1 h postinfection).5. Pei J, Sekellick MJ, Marcus PI, Choi IS, Collisson EW. Chicken
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2001;21:1071–7.
6. Vassao RC, de Franco MT, Hartz D, Modolell M, Sippel AE, Pereira
CA. Down-regulation of Bgp1(a) viral receptor by interferon-gamma
is related to the antiviral state and resistance to mouse hepatitis virus
3 infection. Virology 2000;274:278–83.
7. Minagawa H, Takenaka A, Mohri S, Mori R. Protective effect of
recombinant murine interferon beta against mouse hepatitis virus
infection. Antiviral Res 1987;8:85-95.
8. Panitch H, Goodin DS, Francis G, Chang P, Coyle PK, O’Connor P,
et al. Randomized, comparative study of interferon beta-1a treatment
regimens in MS: The EVIDENCE trial. Neurology 2002;
59:1496–1506.
9. Antonetti F, Finocchiaro O, Mascia M, Terlizzese MG, Jaber A. A
comparison of the biologic activity of two recombinant IFN-beta
preparations used in the treatment of relapsing-remitting multiple
sclerosis. J Interferon Cytokine Res 2002;22:1181-1184.
10. Mager DE, Neuteboom B, Efthymiopoulos C, Munafo A, Jusko WJ.
Receptor-mediated pharmacokinetics and pharmacodynamics of
interferon-β1a following intravenous and subcutaneous dosing in
monkeys. J Pharmacol Exp Ther 2003;306:262–70.
Address for correspondence: Peter B. Jahrling, USAMRIID, Attn:
MCMR-UIZ, 1425 Porter Street, Fort Detrick, MD 21702-5011, USA;
fax: 301-619-4625; email: peter.jahrling@us.army.mil
Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 10, No. 2, February 2004 319
DISPATCH LABORATORY STUDIES
Search p past i issues o of E EID a at w www.cdc.gov/eid